U.S. overdose deaths dropped 27% in 2024

More than 105,000 people in the United States died from a drug overdose in each year from 2021 to 2023. Then, in 2024, overdose deaths fell 27%. Preliminary data from 2025 show another meaningful drop, although mortality remains high. Brandon Marshall, an epidemiologist at Brown University, called the speed of the decline unprecedented — and said the country is still nowhere near out of the crisis.

The puzzle is that no single intervention explains the turn. Evan Gumas, a senior research associate at the Commonwealth Fund, spoke with public health and addiction authorities from at least two dozen U.S. states and other countries. They repeatedly pointed to a combination of wider naloxone distribution, expanded access to medications for opioid use disorder, better treatment in and around prisons, and stronger data infrastructure. Naloxone is the drug that can reverse an opioid overdose, giving people nearby a chance to stop a fatal event.

The local numbers show what that mix can look like. Virginia saw a 40% decrease in overdose deaths from 2023 to 2024 after implementing a plan to make naloxone widely available. Maryland more than doubled its naloxone distribution between 2021 and 2025, using vending machines, emergency medical services and public safety personnel at overdose scenes; the state recorded a 25% decrease from 2019 to 2024. Treatment access also grew: Colorado’s methadone clinics rose from 25 to 54 in five years, while Swedish health authorities linked a concentrated expansion of treatment access to about a 25% reduction in deaths since 2017.

The expansion reached prisons, where substance use disorders are 12 times more common than in the general population and the weeks after release are especially risky. In New York prisons and jails, use of medications for opioid use disorder increased seven times over between 2022 and 2025. At the same time, the drug supply changed: fentanyl potency has declined in recent years, according to Gumas, while contaminants such as xylazine and medetomidine remain dangerous but may not carry fentanyl’s immediate risk of fatality. A darker explanation is also possible: many people at highest risk died during the years of rising mortality, leaving a smaller population at risk.

The concrete change is that a person at risk may now encounter naloxone in more places, more often find access to methadone or buprenorphine, and receive treatment while incarcerated. States also have better tools to track a drug supply that keeps shifting. But the gains are fragile: experts warn that Medicaid cuts and decisions by the Trump administration could weaken access, while the administration has opposed some proven harm-reduction measures even as it generally supports medications for opioid use disorder. Scotland’s preliminary 2025 data may already point to a rise again, reinforcing the need for more research into why the decline varies so widely by place.